Orphan drugs in development for primary biliary cirrhosis: Challenges and progress

Ahmad H. Ali, Thomas J. Byrne, Keith D. Lindor

Research output: Contribution to journalArticle

Abstract

Primary biliary cirrhosis (PBC) is a chronic progressive liver disease that often leads to fibrosis, cirrhosis, and end-stage liver disease. The diagnosis is made when there is evidence of cholestasis and reactivity to the antimitochondrial antibody. The etiology of PBC is poorly understood; however, several lines of evidence suggest an environmental factor that triggers a series of immune-mediated inflammatory reactions in the bile ducts in a genetically susceptible individual. Fatigue and pruritus are the most common symptoms of PBC; however, many patients are diagnosed with PBC only based on laboratory abnormalities. The only pharmacological treatment approved for PBC is ursodeoxycholic acid (UDCA). Several controlled studies have shown that UDCA improves liver biochemistries and prolongs transplant-free survival in PBC patients. Nearly 40% of PBC patients do not respond to UDCA, and those patients are at high risk of serious adverse events, such as the development of liver failure. Therefore, newer alternative therapeutic options for PBC are needed. Obeticholic acid is a first-in-class farnesoid X receptor agonist that has been recently evaluated in PBC patients with inadequate response to UDCA, and demonstrated beneficial results in improving liver biochemistries. Several other agents (fibrates and glucocorticoids) have been previously examined in PBC patients with inadequate response to UDCA, and preliminary results showed biochemical improvement. However, large-scale controlled clinical trials are needed to determine the long-term effects of fibrates and glucocorticoids on the clinical outcomes of PBC. Clinical trials of NGM282 (a fibroblast growth factor-19 analog) and Abatacept (a fusion protein composed of the Fc portion of immunoglobulin G1 fused to CTLA4) are currently underway.

Original languageEnglish (US)
Pages (from-to)83-97
Number of pages15
JournalOrphan Drugs: Research and Reviews
Volume5
DOIs
StatePublished - 2015

Fingerprint

Orphan Drug Production
Biliary Liver Cirrhosis
Ursodeoxycholic Acid
Fibric Acids
Biochemistry
Glucocorticoids
Fibrosis
Immunoglobulin Fc Fragments
End Stage Liver Disease
Fibroblast Growth Factors
Liver
Cholestasis
Controlled Clinical Trials
Liver Failure
Pruritus
Bile Ducts
Fatigue
Liver Diseases

Keywords

  • Antimitochondrial antibody
  • Farnesoid x receptor
  • Fibrates
  • Glucocorticoids
  • Primary biliary cirrhosis

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmaceutical Science

Cite this

Orphan drugs in development for primary biliary cirrhosis : Challenges and progress. / Ali, Ahmad H.; Byrne, Thomas J.; Lindor, Keith D.

In: Orphan Drugs: Research and Reviews, Vol. 5, 2015, p. 83-97.

Research output: Contribution to journalArticle

Ali, Ahmad H. ; Byrne, Thomas J. ; Lindor, Keith D. / Orphan drugs in development for primary biliary cirrhosis : Challenges and progress. In: Orphan Drugs: Research and Reviews. 2015 ; Vol. 5. pp. 83-97.
@article{61812f05d8f548d0990eb38227c0110a,
title = "Orphan drugs in development for primary biliary cirrhosis: Challenges and progress",
abstract = "Primary biliary cirrhosis (PBC) is a chronic progressive liver disease that often leads to fibrosis, cirrhosis, and end-stage liver disease. The diagnosis is made when there is evidence of cholestasis and reactivity to the antimitochondrial antibody. The etiology of PBC is poorly understood; however, several lines of evidence suggest an environmental factor that triggers a series of immune-mediated inflammatory reactions in the bile ducts in a genetically susceptible individual. Fatigue and pruritus are the most common symptoms of PBC; however, many patients are diagnosed with PBC only based on laboratory abnormalities. The only pharmacological treatment approved for PBC is ursodeoxycholic acid (UDCA). Several controlled studies have shown that UDCA improves liver biochemistries and prolongs transplant-free survival in PBC patients. Nearly 40{\%} of PBC patients do not respond to UDCA, and those patients are at high risk of serious adverse events, such as the development of liver failure. Therefore, newer alternative therapeutic options for PBC are needed. Obeticholic acid is a first-in-class farnesoid X receptor agonist that has been recently evaluated in PBC patients with inadequate response to UDCA, and demonstrated beneficial results in improving liver biochemistries. Several other agents (fibrates and glucocorticoids) have been previously examined in PBC patients with inadequate response to UDCA, and preliminary results showed biochemical improvement. However, large-scale controlled clinical trials are needed to determine the long-term effects of fibrates and glucocorticoids on the clinical outcomes of PBC. Clinical trials of NGM282 (a fibroblast growth factor-19 analog) and Abatacept (a fusion protein composed of the Fc portion of immunoglobulin G1 fused to CTLA4) are currently underway.",
keywords = "Antimitochondrial antibody, Farnesoid x receptor, Fibrates, Glucocorticoids, Primary biliary cirrhosis",
author = "Ali, {Ahmad H.} and Byrne, {Thomas J.} and Lindor, {Keith D.}",
year = "2015",
doi = "10.2147/ODRR.S69477",
language = "English (US)",
volume = "5",
pages = "83--97",
journal = "Orphan Drugs: Research and Reviews",
issn = "2230-6161",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Orphan drugs in development for primary biliary cirrhosis

T2 - Challenges and progress

AU - Ali, Ahmad H.

AU - Byrne, Thomas J.

AU - Lindor, Keith D.

PY - 2015

Y1 - 2015

N2 - Primary biliary cirrhosis (PBC) is a chronic progressive liver disease that often leads to fibrosis, cirrhosis, and end-stage liver disease. The diagnosis is made when there is evidence of cholestasis and reactivity to the antimitochondrial antibody. The etiology of PBC is poorly understood; however, several lines of evidence suggest an environmental factor that triggers a series of immune-mediated inflammatory reactions in the bile ducts in a genetically susceptible individual. Fatigue and pruritus are the most common symptoms of PBC; however, many patients are diagnosed with PBC only based on laboratory abnormalities. The only pharmacological treatment approved for PBC is ursodeoxycholic acid (UDCA). Several controlled studies have shown that UDCA improves liver biochemistries and prolongs transplant-free survival in PBC patients. Nearly 40% of PBC patients do not respond to UDCA, and those patients are at high risk of serious adverse events, such as the development of liver failure. Therefore, newer alternative therapeutic options for PBC are needed. Obeticholic acid is a first-in-class farnesoid X receptor agonist that has been recently evaluated in PBC patients with inadequate response to UDCA, and demonstrated beneficial results in improving liver biochemistries. Several other agents (fibrates and glucocorticoids) have been previously examined in PBC patients with inadequate response to UDCA, and preliminary results showed biochemical improvement. However, large-scale controlled clinical trials are needed to determine the long-term effects of fibrates and glucocorticoids on the clinical outcomes of PBC. Clinical trials of NGM282 (a fibroblast growth factor-19 analog) and Abatacept (a fusion protein composed of the Fc portion of immunoglobulin G1 fused to CTLA4) are currently underway.

AB - Primary biliary cirrhosis (PBC) is a chronic progressive liver disease that often leads to fibrosis, cirrhosis, and end-stage liver disease. The diagnosis is made when there is evidence of cholestasis and reactivity to the antimitochondrial antibody. The etiology of PBC is poorly understood; however, several lines of evidence suggest an environmental factor that triggers a series of immune-mediated inflammatory reactions in the bile ducts in a genetically susceptible individual. Fatigue and pruritus are the most common symptoms of PBC; however, many patients are diagnosed with PBC only based on laboratory abnormalities. The only pharmacological treatment approved for PBC is ursodeoxycholic acid (UDCA). Several controlled studies have shown that UDCA improves liver biochemistries and prolongs transplant-free survival in PBC patients. Nearly 40% of PBC patients do not respond to UDCA, and those patients are at high risk of serious adverse events, such as the development of liver failure. Therefore, newer alternative therapeutic options for PBC are needed. Obeticholic acid is a first-in-class farnesoid X receptor agonist that has been recently evaluated in PBC patients with inadequate response to UDCA, and demonstrated beneficial results in improving liver biochemistries. Several other agents (fibrates and glucocorticoids) have been previously examined in PBC patients with inadequate response to UDCA, and preliminary results showed biochemical improvement. However, large-scale controlled clinical trials are needed to determine the long-term effects of fibrates and glucocorticoids on the clinical outcomes of PBC. Clinical trials of NGM282 (a fibroblast growth factor-19 analog) and Abatacept (a fusion protein composed of the Fc portion of immunoglobulin G1 fused to CTLA4) are currently underway.

KW - Antimitochondrial antibody

KW - Farnesoid x receptor

KW - Fibrates

KW - Glucocorticoids

KW - Primary biliary cirrhosis

UR - http://www.scopus.com/inward/record.url?scp=84959325729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959325729&partnerID=8YFLogxK

U2 - 10.2147/ODRR.S69477

DO - 10.2147/ODRR.S69477

M3 - Article

AN - SCOPUS:84959325729

VL - 5

SP - 83

EP - 97

JO - Orphan Drugs: Research and Reviews

JF - Orphan Drugs: Research and Reviews

SN - 2230-6161

ER -